logo
  

GSK: FDA, EMA Conclude No Evidence Of Association Between Ranitidine Therapy And Cancer Development

British drug maker GSK plc (GSK,GSK.L), in its statement on Zantac (ranitidine) litigation and N-nitrosodimethylamine or NDMA, said the U.S. and European regulators have concluded there is no evidence of a causal association between ranitidine therapy and the development of cancer.

The company noted that substantial scientific evidence supports the conclusion of the U.S. Food & Drug Administration, and the European Medicines Agency.

GSK said the plaintiff litigation is inconsistent with the scientific consensus, and that the company will vigorously defend all claims.

The statement was issued in response to recent speculative commentary regarding U.S. Zantac litigation.

GSK has been named as a defendant in around 3,000 filed personal injury cases in federal and state court and numerous unfiled claims registered in a census established by the Court presiding over the Zantac Multidistrict Litigation (MDL) proceeding.

Since the issue concerning the presence of NDMA in ranitidine arose in 2019, GSK noted that the company, independent cancer researchers, the FDA and the EMA have all undertaken extensive reviews of available data and conducted numerous investigations.

Based on these investigations and experiments, all have concluded that there is no evidence of a causal association between the therapy and the cancer development. These conclusions pertain to all forms of cancer.

In November 2019, the FDA determined that levels of NDMA in ranitidine products are similar to levels in common foods like grilled and smoked meats, and that it would conduct tests to fully understand if ranitidine forms NDMA in the human body.

In September 2020, the EMA's comprehensive review of epidemiological and post marketing data concluded there is "no evidence of a causal association between ranitidine therapy and the development of cancer in patients."

In June 2021, the FDA reported that its testing did not support that ranitidine is converted to NDMA in a general, healthy population.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.
Follow RTT